Author (study name) Year Radiation (Gy/fractions) Chemotherapy N of patients Overall survival Grade 3–4 pneumonitis (%) Treatment-related death (%) Induction Concurrent Consolidation Median (month) 2y rate (%) Hallqvist A (SATELLITE)…
Target Agent Study phase Result References VEGF-A Bevacizumab II Promising [20] II Promising [21] II Positive for PFS, but no benefit in OS [22] VEGFR-1, VEGFR-2, VEGFR-3 Cediranib II Negative…
Fig. 6.1 Typical primary analysis pipeline of WES (a) and WTS (b). Briefly, data processing is done as follows: data cleansing, mapping to reference genome, and variant call/read counting and…
(1) Research Oncology, Guy’s Hospital, London, United Kingdom Abstract There is substantial evidence of deleterious health behaviour in males both in terms of high-risk activities and avoidance of contact…
(1) Research Oncology, Guy’s Hospital, London, United Kingdom Abstract Breast cancer is rare in men and most males referred to breast clinics will have benign conditions, frequently true or…
(1) Research Oncology, Guy’s Hospital, London, United Kingdom Abstract A rare disease can be a source of worry for both the patient and the doctor. There is one approach…
(1) Research Oncology, Guy’s Hospital, London, United Kingdom Abstract In many series of MBC cases the majority had stage III/IV disease at presentation and this has shown little improvement…
(1) Research Oncology, Guy’s Hospital, London, United Kingdom Abstract No randomised controlled trials of adjuvant therapy have been conducted with MBC patients so that the results from large trials…
(1) Research Oncology, Guy’s Hospital, London, United Kingdom Abstract Age is a major risk factor for MBC with Clemmesen’s hook present on the age-incidence curve. Male/female incidence ratios are…
